Current treatment status-Undergoing active treatment-Progressive despite several lines of treatment Posts on Medivizor
Navigation Menu

Current treatment status-Undergoing active treatment-Progressive despite several lines of treatment Posts on Medivizor

Is Ixazomib, thalidomide and dexamethasone effective in treating relapsed and/or refractory multiple myeloma?

Is Ixazomib, thalidomide and dexamethasone effective in treating relapsed and/or refractory multiple myeloma?

Posted by on Jul 11, 2021 in Multiple Myeloma | 0 comments

In a nutshell This article looked at the effectiveness and safety of continuous ixazomib (Ninlaro), thalidomide (Thalomid), and dexamethasone (Decadron) (ITd) in the treatment of relapsed and/or refractory (RR) multiple myeloma (MM). The authors found that this regimen was well tolerated and showed promising effectiveness in the treatment of...

Read More

Evaluating loncastuximab tesirine for patients with recurrent or hard-to-treat DLBCL

Evaluating loncastuximab tesirine for patients with recurrent or hard-to-treat DLBCL

Posted by on Jul 11, 2021 in Non-Hodgkin lymphoma | 0 comments

In a nutshell This study evaluated the safety and effectiveness of loncastuximab tesirine (Zynlonta) for patients with diffuse large B-cell lymphoma (DLBCL) that returned or stopped responding to treatment. This study concluded that this treatment was safe and effective for these patients. Some background DLBCL is one of the most common types of...

Read More

Evaluating CAR T-cell therapy before stem cell transplantation for patients with B-cell ALL

Evaluating CAR T-cell therapy before stem cell transplantation for patients with B-cell ALL

Posted by on Jul 11, 2021 in Leukemia | 0 comments

In a nutshell This study evaluated the safety and effectiveness of CAR T-cell therapy versus chemotherapy before a stem cell transplant (SCT) for patients with recurrent or non-responsive B-cell acute lymphoblastic lymphoma (B-ALL). The authors concluded that CAR T-cell therapy followed by SCT was safe and effective for these patients. Some background...

Read More

Evaluating long-term effectiveness and safety of venetoclax patients with for non-Hodgkin lymphoma

Evaluating long-term effectiveness and safety of venetoclax patients with for non-Hodgkin lymphoma

Posted by on Jul 11, 2021 in Non-Hodgkin lymphoma | 0 comments

In a nutshell This early study looked at the long-term results of the targeted treatment venetoclax (Venclexta) for patients with relapsed non-Hodgkin lymphoma (NHL). It found that venetoclax is a safe and effective treatment and that some patients have a durable response. Some background NHL is a group of cancers of a type of white blood...

Read More

Comparing pembrolizumab and brentuximab vedotin for the treatment of patients with relapsed or refractory classical Hodgkin lymphoma.

Comparing pembrolizumab and brentuximab vedotin for the treatment of patients with relapsed or refractory classical Hodgkin lymphoma.

Posted by on Jun 27, 2021 in Hodgkin's lymphoma | 0 comments

In a nutshell The authors compared the safety and effectiveness of pembrolizumab (Keytruda) and brentuximab vedotin (BV; Adcetris) for the treatment of patients with relapsed or refractory (r/r) classical Hodgkin lymphoma (cHL). The study found that pembrolizumab had better survival without cancer worsening compared to BV in these...

Read More

Is CAR T-cell therapy more effective than salvage therapy for patients with DLBCL?

Is CAR T-cell therapy more effective than salvage therapy for patients with DLBCL?

Posted by on May 30, 2021 in Non-Hodgkin lymphoma | 0 comments

In a nutshell This study compared the effectiveness of T-cell therapy to salvage chemotherapy in patients with recurrent or hard-to-treat diffuse large B-cell lymphoma (DLBCL). This study found that lisocabtagene maraleucel (liso-cel; Breyanzi) T-cell therapy was more effective than salvage chemotherapy for these patients. Some background DLBCL is one...

Read More

Copanlisib plus rituximab improves survival in patients with relapsed painless non-Hodgkin lymphoma.

Copanlisib plus rituximab improves survival in patients with relapsed painless non-Hodgkin lymphoma.

Posted by on May 22, 2021 in Non-Hodgkin lymphoma | 0 comments

In a nutshell This study reported the effectiveness and safety outcomes of copanlisib (Aliqopa) and rituximab (Rituxan) combination for the treatment of patients with relapsed indolent (painless) non-Hodgkin lymphoma (NHL). The data showed that this combination improved the outcomes of these patients with manageable side effects. Some background...

Read More

Is autologous stem cell transplantation after anti-PD-1 therapy an effective treatment for patients with relapsed or refractory Hodgkin lymphoma?

Is autologous stem cell transplantation after anti-PD-1 therapy an effective treatment for patients with relapsed or refractory Hodgkin lymphoma?

Posted by on May 15, 2021 in Hodgkin's lymphoma | 0 comments

In a nutshell The authors assessed the effectiveness of autologous stem cell transplantation (ASCT) after anti-PD-1 therapy for the treatment of patients with high-risk relapsed/refractory (r/r) Hodgkin lymphoma (HL). The study found that ASCT after anti-PD-1 therapy had very good outcomes in patients with r/r HL. Some background Standard...

Read More

Searching for patients with solid tumors with abnormal genetic changes to trial an experimental medication

Searching for patients with solid tumors with abnormal genetic changes to trial an experimental medication

Posted by on Apr 30, 2021 in Melanoma | 0 comments

In a nutshell This study is searching for participants with advanced solid tumors including melanoma to examine the safety and effectiveness of experimental drug avapritinib (Ayvakit). The main outcomes to be measured are the response to treatment and side effects. This trial is being conducted in Texas, US. The details Some cancers grow as a...

Read More

Searching for patients with solid tumors with abnormal genetic changes to trial an experimental medication

Searching for patients with solid tumors with abnormal genetic changes to trial an experimental medication

Posted by on Apr 30, 2021 in Lung cancer | 0 comments

In a nutshell This study is searching for participants with advanced solid tumors including lung cancer to examine the safety and effectiveness of experimental drug avapritinib (AYVAKIT). The main outcomes to be measured are the response to treatment and side effects. This trial is being conducted in Texas, US. The details Some cancers grow as a...

Read More

Searching for patients with solid tumors with abnormal genetic changes to trial an experimental medication

Searching for patients with solid tumors with abnormal genetic changes to trial an experimental medication

Posted by on Apr 30, 2021 in Colorectal cancer | 0 comments

In a nutshell This study is searching for participants with advanced solid tumors including colorectal cancer to examine the safety and effectiveness of experimental drug avapritinib (AYVAKIT). The main outcomes to be measured are the response to treatment and side effects. This trial is being conducted in Texas, US. The details Some cancers grow as a...

Read More

Evaluating pirtobrutinib for the treatment on B cell leukemia/lymphoma

Evaluating pirtobrutinib for the treatment on B cell leukemia/lymphoma

Posted by on Apr 30, 2021 in Non-Hodgkin lymphoma | 0 comments

In a nutshell This study tested the safety and effectiveness of pirtobrutinib (LOXO-305) in the treatment of patients with B cell leukemia/lymphoma. The authors found that pirtobrutinib was safe and had promising effectiveness in these patients. Some background B cells are a type of cell of the immune system. Some lymphomas and leukemias such as...

Read More